Business
CFN Media Exclusive CEO Interview: Abattis Validates Lab Strategy, Sets Stage for Rapid Growth
CFN Media Exclusive CEO Interview: Abattis Validates Lab Strategy, Sets Stage for Rapid Growth.
About this update from Abattis Bioceuticals Corp
[{"type":"text","content":"\n \n \n CFN Media Exclusive CEO Interview: Abattis Validates Lab Strategy, Sets Stage for Rapid Growth\n \n \nCFN Media Exclusive CEO Interview: Abattis Validates Lab Strategy, Sets Stage for Rapid Growth\n \n SEATTLE, WA--(Marketwired - Nov 6, 2017) - CFN Media Group (\"CannabisFN\"), the leading creative agency and media network dedicated to legal cannabis, announces publication of an exclusive executive interview with Rob Abenante, CEO of Abattis Bioceuticals Corp. (CSE: ATT) (CNSX: ATT) (CNSX: ATT.CN) (OTCQB: ATTBF). In the interview, Mr. Abenante discusses the company's cannabis testing and product development strategy in light of the recently announced partnership with Emerald Health Therapeutics.\n CFN: Let's talk about the general lay of the land in the cannabis industry, especially in Canada with full legalization on the horizon. A lot of market focus has been on Licensed Producers ramping up production capability to meet an anticipated shortfall of supply. It seems that at some point, cannabis flower product will become commoditized and offer less upside than cannabis-based products like extracts, edibles, nutraceuticals and medicines. How do you see this playing out?\n RA: I think that is generally the right take. Companies can differentiate their cannabis flower products only to a point, and given the way production capabilities are increasing in anticipation of legalization, aggressive price competition is inevitable. Licensed producers are already looking for ways to expand revenue streams and make their brand stand out by researching and developing associated products. The big news in the market recently is the Constellation Brands investment in Canopy Growth and the beverage products planned under that agreement. That is a prime illustration of the development of the industry. \n At Abattis, we view our laboratory business as the prime vehicle to take advantage of these trends. The Dealer's License, or Controlled Substances License, we possess is different from the licenses held by the producers. It allows us to handle all cannabis derivatives for research, development, extraction, formulation and testing purposes. So we can develop products derived from the plant and ultimately sell them through our Vergence sales and marketing channels. We can also partner with producers to co-develop or white label cannabis d...